East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based (Q87358563)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 February 2016

Language	Label	Description	Also known as
English	East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based	scientific article published on 22 February 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL) (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

based on heuristic

inferred from title

author name string

Keunchil Park

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Joo-Hang Kim

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Eun Kyung Cho

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jin-Hyoung Kang

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jin-Yuan Shih

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Annamaria Hayden Zimmermann

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Pablo Lee

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Ekaterine Alexandris

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Tarun Puri

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Mauro Orlando

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

22 February 2016

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Cancer Research and Treatment

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

48

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1177-1186

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

22 February 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Asian ethnicity is a favorable prognostic factor for overall survival in non-small cell lung cancer (NSCLC) and is independent of smoking status.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Halting angiogenesis suppresses carcinoma cell invasion

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC

1 reference

https://pubmed.ncbi.nlm.nih.gov/26910471

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4143/CRT.2015.401

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26910471%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87358563&oldid=1852601772"